70 related articles for article (PubMed ID: 15177492)
1. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
Punt CJ; de Jonge MJ; Monfardini S; Daugaard G; Fiedler W; Baron B; Lacombe D; Fumoleau P;
Eur J Cancer; 2004 Jun; 40(9):1332-4. PubMed ID: 15177492
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
Baka S; Ranson M; Lorigan P; Danson S; Linton K; Hoogendam I; Mettinger K; Thatcher N
Eur J Cancer; 2005 Jul; 41(11):1547-50. PubMed ID: 16026691
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
[TBL] [Abstract][Full Text] [Related]
4. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer.
Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
Cancer Chemother Pharmacol; 2006 Jul; 58(1):86-90. PubMed ID: 16447041
[TBL] [Abstract][Full Text] [Related]
5. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
Yamamoto N; Tsurutani J; Yoshimura N; Asai G; Moriyama A; Nakagawa K; Kudoh S; Takada M; Minato Y; Fukuoka M
Anticancer Res; 2006; 26(1B):777-81. PubMed ID: 16739353
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Burris HA; Rivkin S; Reynolds R; Harris J; Wax A; Gerstein H; Mettinger KL; Staddon A
Oncologist; 2005 Mar; 10(3):183-90. PubMed ID: 15793221
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
11. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).
Christodoulou C; Kalofonos HP; Briasoulis E; Bafaloukos D; Makatsoris T; Koutras A; Skarlos DV; Samantas E
Cancer Chemother Pharmacol; 2006 Jan; 57(2):207-12. PubMed ID: 16028103
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Duffaud F; Borner M; Chollet P; Vermorken JB; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
Eur J Cancer; 2004 Dec; 40(18):2748-52. PubMed ID: 15571957
[TBL] [Abstract][Full Text] [Related]
15. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U
Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
Stathopoulos GP; Christodoulou Ch; Stathopoulos J; Skarlos D; Rigatos SK; Giannakakis T; Armenaki O; Antoniou D; Athanasiadis A; Giamboudakis P; Dimitroulis J; Georgatou N; Katis K
Cancer Chemother Pharmacol; 2006 Jun; 57(6):796-800. PubMed ID: 16142488
[TBL] [Abstract][Full Text] [Related]
18. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
[TBL] [Abstract][Full Text] [Related]
20. Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
de Jonge MJ; Droz JP; Paz-Ares L; van Oosterom AT; de Wit R; Chollet P; Baron B; Lacombe D; Mettinger K; Fumoleau P;
Invest New Drugs; 2004 Aug; 22(3):329-33. PubMed ID: 15122081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
